TransMedics Group Stock (NASDAQ:TMDX)


ForecastChart

Previous Close

$105.60

52W Range

$55.00 - $177.37

50D Avg

$125.97

200D Avg

$92.46

Market Cap

$3.72B

Avg Vol (3M)

$1.00M

Beta

2.05

Div Yield

-

TMDX Company Profile


TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

728

IPO Date

May 02, 2019

Website

TMDX Performance


Latest Earnings Call Transcripts


Q2 22Aug 02, 22 | 12:37 AM
Q1 22May 03, 22 | 11:18 PM
Q4 21Feb 23, 22 | 10:52 PM

Peer Comparison


TickerCompany
INSPInspire Medical Systems, Inc.
CLPTClearPoint Neuro, Inc.
OMOutset Medical, Inc.